T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance

We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge...

Descripción completa

Detalles Bibliográficos
Autores principales: Noetzli, Jasmine, Gavillet, Mathilde, Masouridi‐Levrat, Stavroula, Duchosal, Michel, Spertini, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538043/
https://www.ncbi.nlm.nih.gov/pubmed/28781850
http://dx.doi.org/10.1002/ccr3.1032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538043/
https://www.ncbi.nlm.nih.gov/pubmed/28781850
http://dx.doi.org/10.1002/ccr3.1032

Ejemplares similares